[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598726":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":69,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Jiangsu Province Nanjing Brain Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","EXPERIMENTAL","Switching from Oral Antipsychotics to Paliperidone Palmitate Injection in the Treatment of Schizophrenia Patients",[13],"Drug: Paliperidone Palmitate Injection (PP1M)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Paliperidone Palmitate Injection (PP1M)","Day 0: 150 mg deltoid injection; Day 7: 100 mg deltoid injection; Monthly maintenance dose of 75-150 mg (deltoid or gluteal) for 6 months (dose adjusted per investigator's judgment).\n\nTo avoid missed doses, administration is permitted ±7 days around the scheduled monthly date.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Hao Tang, MD","CONTACT","+86 18913821366","tanghao997@163.com",[28],{"facility":29,"status":20,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Nanjing Brain Hospital","Nanjing","Jiangsu","210024","China","CN",{"type":36,"coordinates":37},"Point",[38,39],118.77778,32.06167,{"lat":39,"lon":38},[42],{"name":23,"role":24,"phone":43,"phoneExt":20,"email":26},"+86 18913821399",{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100598726","phase-4-efficacy-and-functional-recovery-after-switching-from-paliperidone-palmitate-injection-to-oral-antipsychotics-in-schizophrenia-100598726",false,"NCT07075237","Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia","A Study on the Efficacy and Functional Recovery of Switching From Oral Antipsychotics to Paliperidone Palmitate Injection in the Treatment of Schizophrenia","Inclusion Criteria:\n\n1. Outpatients or inpatients meeting DSM-5 diagnostic criteria forschizophrenia;\n2. Aged 18-65 years (inclusive), regardless of gender;\n3. Currently receiving first- or second-generation oral antipsychotics (excluding clozapine) with stable condition as assessed by the investigator, and PANSS total score ≤80 at screening and baseline;\n4. Signed informed consent by the patient and\u002For guardian;\n\nExclusion Criteria:\n\n1. Comorbid psychiatric diagnoses other than schizophrenia;\n2. Severe physical diseases, intellectual disability, organic brain disorders, or mental disorders due to physical illnesses;\n3. QTc interval \\>450 ms (male) or \\>460 ms (female);\n4. History of psychoactive substance abuse (excluding tobacco) within the past 12 months, or significant suicidal\u002Fviolent tendencies;\n5. Current or history of tardive dyskinesia (TD), neuroleptic malignant syndrome (NMS), or severe extrapyramidal symptoms (EPS);\n6. Treatment-resistant schizophrenia (failure of ≥2 adequate antipsychotic regimens of different compounds);\n7. Hypersensitivity or inefficacy to risperidone or paliperidone; 8. Pregnancy, lactation, planned pregnancy, or failure to use effective contraception during the study;\n\n9\\. Other conditions deemed unsuitable by the investigator. \\|","ALL","18 Years","65 Years",{"count":57,"type":58},120,"ESTIMATED","INTERVENTIONAL",[61],"PHASE4","To evaluate the efficacy of Paliperidone Palmitate Injection in replacing oral antipsychotics for the treatment of schizophrenia and its impact on social function",[64],"Schizophrenia",[64,66,67,68],"Paliperidone Palmitate","Oral antipsychotics","Social function|","NOT_YET_RECRUITING","2025-09-24",{"date":72,"type":73},"2025-09-29","ACTUAL",{"date":75,"type":58},"2025-10",{"date":77,"type":58},"2027-03",{"name":5,"class":6},1]